Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors  and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

Denmark: A recent study published in the Journal of Diabetes and its Complications has explored the role of kidney fat ...